Protein Tyrosine Kinase 6 (PTK6) is a non-receptor type tyrosine kinase that may be involved in some cancers. However, the biological role and expression status of PTK6 in pancreatic cancer is unknown. Therefore in this study, we evaluated the functional role of PTK6 on pancreatic cancer invasion. Five pancreatic cancer cell lines expressed PTK6 at varying levels. PTK6 expression was also observed in human pancreatic adenocarcinomas. PTK6 suppression by siRNA significantly reduced both cellular migration and invasion (0.59/0.49 fold for BxPC3, 0.61/0.62 for Panc1, 0.42/0.39 for MIAPaCa2, respectively, p<0.05 for each). In contrast, forced overexpression of PTK6 by transfection of a PTK6 expression vector in Panc1 and MIAPaCa2 cells increased cellular migration and invasion (1.57/1.67 fold for Panc1, 1.44/1.57 for MIAPaCa2, respectively, p<0.05). Silencing PTK6 reduced ERK1/2 activation, but not AKT or STAT3 activation, while PTK6 overexpression increased ERK1/2 activation. U0126, a specific inhibitor of ERK1/2, completely abolished the effect of PTK6 overexpression on cellular migration and invasion. These results suggest that PTK6 regulates cellular migration and invasion in pancreatic cancer via ERK signaling. PTK6 may be a novel therapeutic target for pancreatic cancer.
References
[1]
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29. doi: 10.3322/caac.20138
[2]
Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362: 1605–1617. doi: 10.1056/nejmra0901557
[3]
Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, et al. (1994) Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 9: 2383–2390.
[4]
Siyanova EY, Serfas MS, Mazo IA, Tyner AL (1994) Tyrosine kinase gene expression in the mouse small intestine. Oncogene 9: 2053–2057.
[5]
Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, et al. (1995) A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene 10: 349–357.
[6]
Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, et al. (2006) The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5: 1136–1141. doi: 10.4161/cbt.5.9.2953
[7]
Derry JJ, Prins GS, Ray V, Tyner AL (2003) Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 22: 4212–4220. doi: 10.1038/sj.onc.1206465
[8]
Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, et al. (1999) BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 5: 1767–1777.
[9]
Easty DJ, Mitchell PJ, Patel K, Florenes VA, Spritz RA, et al. (1997) Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer 71: 1061–1065. doi: 10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f
[10]
Born M, Quintanilla-Fend L, Braselmann H, Reich U, Richter M, et al. (2005) Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J Pathol 205: 592–596. doi: 10.1002/path.1720
[11]
Barker KT, Jackson LE, Crompton MR (1997) BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 15: 799–805. doi: 10.1038/sj.onc.1201241
[12]
Zhao C, Chen Y, Zhang W, Zhang J, Xu Y, et al. (2013) Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance. Onco Targets Ther 6: 183–188. doi: 10.2147/ott.s41283
[13]
Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, et al. (2004) Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 24: 10558–10572. doi: 10.1128/mcb.24.24.10558-10572.2004
[14]
Shen CH, Chen HY, Lin MS, Li FY, Chang CC, et al. (2008) Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res 68: 7779–7787. doi: 10.1158/0008-5472.can-08-0997
[15]
Castro NE, Lange CA (2010) Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res 12: R60. doi: 10.1186/bcr2622
[16]
Liu L, Gao Y, Qiu H, Miller WT, Poli V, et al. (2006) Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 25: 4904–4912. doi: 10.1038/sj.onc.1209501
[17]
Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, et al. (1996) Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 271: 30956–30963. doi: 10.1074/jbc.271.48.30956
[18]
Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, et al. (2005) Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 280: 1982–1991.
[19]
Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA (2007) Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 67: 4199–4209. doi: 10.1158/0008-5472.can-06-3409
[20]
Miah S, Martin A, Lukong KE (2012) Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo. Oncogenesis 1: e11. doi: 10.1038/oncsis.2012.11
[21]
Harvey AJ, Crompton MR (2003) Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 22: 5006–5010. doi: 10.1038/sj.onc.1206577
[22]
Chakraborty G, Jain S, Kundu GC (2008) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152–161. doi: 10.1158/0008-5472.can-07-2126
[23]
Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, et al. (2010) PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5: e11729. doi: 10.1371/journal.pone.0011729
[24]
Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, et al.. (2012) Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 143: 675–686 e671–612.
[25]
Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, et al. (2013) PTK6 Activation at the Membrane Regulates Epithelial-Mesenchymal Transition in Prostate Cancer. Cancer Res 73: 5426–5437. doi: 10.1158/0008-5472.can-13-0443
[26]
Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, et al. (2004) Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 64: 7439–7446. doi: 10.1158/0008-5472.can-04-1177
[27]
Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E (2013) Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 32: 147–162. doi: 10.1007/s10555-012-9396-2
[28]
Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, et al. (2012) KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res 72: 2554–2564. doi: 10.1158/0008-5472.can-11-3552
[29]
Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56: 1134–1152.
[30]
Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, et al. (2007) PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 96: 801–807.
[31]
Aubele M, Walch AK, Ludyga N, Braselmann H, Atkinson MJ, et al. (2008) Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br J Cancer 99: 1089–1095. doi: 10.1158/0008-5472.sabcs-3073
[32]
Liu LN, Huang PY, Lin ZR, Hu LJ, Liang JZ, et al. (2013) Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis. J Transl Med 11: 140. doi: 10.1186/1479-5876-11-140
[33]
Liu XK, Zhang XR, Zhong Q, Li MZ, Liu ZM, et al. (2013) Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. J Transl Med 11: 59. doi: 10.1186/1479-5876-11-59
